Radiation oncology services in the modern era: Evolving patterns of usage and payments in the office setting for medicare patients from 2000 to 2010

Journal of Oncology Practice

Volumn 10, Issue 4, 2013, Pages e201-e207

  Shen, Xinglei ^a   Showalter, Timothy N ^a   Mishra, Mark V ^a   Barth, Sanford ^a   Rao, Vijay ^a   Levin, David ^a   Parker, Laurence ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CENTER; HEALTH CARE DELIVERY; HEALTH SERVICE; HOSPITAL; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDICAL PRACTICE; MEDICARE; ONCOLOGY; OUTPATIENT; ECONOMICS; HEALTH CARE COST; HISTORY; MEDICAL FEE; ORGANIZATION AND MANAGEMENT; TRENDS; UNITED STATES;

FEE-FOR-SERVICE PLANS; HEALTH CARE COSTS; HISTORY, 21ST CENTURY; HUMANS; MEDICARE; RADIATION ONCOLOGY; UNITED STATES;

EID: 84919973375     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2013.001270     Document Type: Article

References (17)

1. Keehan SP, Sisko AM, Truffer CJ, et al: National health spending projections through 2020: Economic recovery and reform drive faster spending growth. Health Aff (Millwood) 30:1594-1605, 2011
2. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
3. Malik NN: Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol 6:550-552, 2009
4. Schnipper LE, Smith TJ, Raghavan D, et al: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715-1724, 2012
5. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 151:716-726, W-236, 2009
6. Moyer VA, U.S. Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157:120-134, 2012
7. National Cancer Institute: Radiation Therapy and You: Support for People With Cancer. Bethesda, MD, National Cancer Institute, 2012
8. Jensen SB, Pedersen AM, Vissink A, et al: A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Management strategies and economic impact. Support Care Cancer 18:1061-1079, 2010
9. Ohri N, Dicker AP, Showalter TN: Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol 19:6373-6380, 2012
10. van Loon J, Grutters J, Macbeth F: Evaluation of novel radiotherapy technologies: What evidence is needed to assess their clinical and cost effectiveness, and how should we get it? Lancet Oncol 13:e169-e177, 2012
11. Jacobs BL, Zhang Y, Skolarus TA, et al: Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood) 31:750-759, 2012
12. Smith BD, Pan IW, Shih YC, et al: Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 103:798-809, 2011
13. Bujold A, Craig T, Jaffray D, et al: Image-guided radiotherapy: Has it influenced patient outcomes? Semin Radiat Oncol 22:50-61, 2012
14. Mitchell JM: Urologists' use of intensity-modulated radiation therapy for prostate cancer. N Engl J Med 369:1629-1637, 2013
15. Roehrig C, Turner A, Hughes-Cromwick P, et al: When the cost curve bent - Pre-recession moderation in health care spending. N Engl J Med 367:590-593, 2012
16. Nguyen PL, Gu X, Lipsitz SR, et al: Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29:1517-1524, 2011
17. Sher DJ, Neville BA, Chen AB, et al: Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: A SEER-Medicare analysis. Int J Radiat Oncol Biol Phys 81:e197-e206, 2011